AV7909 + doxycycline

AV7909 + doxycycline is the combined use of the AV7909 vaccine (Anthrax Vaccine Adsorbed, Adjuvanted; comprising Anthrax Vaccine Adsorbed with a CpG 7909 adjuvant) and the antibacterial agent doxycycline. This combination is developed and evaluated for **post-exposure prophylaxis (PEP) of disease resulting from suspected or confirmed Bacillus anthracis (anthrax) exposure**. AV7909 functions as an immunization: CpG 7909 binds Toll-like receptor 9 to enhance immune responses, specifically generating neutralizing antibodies to anthrax protective antigen. Doxycycline is a tetracycline-class small molecule antibiotic inhibiting protein synthesis in susceptible bacteria by binding the 30S ribosomal subunit. Clinical studies show that coadministration of AV7909 and doxycycline has no clinically significant effect on either agent's pharmacokinetics or immunogenicity, and the combination is well tolerated. This approach reflects CDC and FDA guidance for anthrax PEP, in which AV7909 immunization is administered intramuscularly while a full course of doxycycline is taken orally[1][2][3][5][6][7].